CD8A and neoplasm: Increased CD8+ TILs could be explained in part with ASA + anti-VEGF antibody treatment; in agreement with our previous study19, tumor endothelial FasL expression was reduced in Groups B and C animals receiving these two agents, and a positive correlation with increased CD8+ TILs was also observed.